Results 11 to 20 of about 72,887 (326)
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy [PDF]
Frontiers in Pharmacology, 2020 Poly(ADP-ribose)polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the nuclei of mammalian cells, with a structure and function that have attracted interest since its discovery.
Stephen A. Jannetti +10 more
doaj +3 more sources
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
Taiwanese Journal of Obstetrics & Gynecology, 2017 Chia-Hao Liu, Yi Chang
doaj +3 more sources
Poly(ADP-Ribose) Polymerase Inhibitors [PDF]
Journal of Thoracic Oncology, 2010 This session not only described several poly(ADP-ribose) polymerase (PARP) inhibitors but also included talks on the science of nuclear excision repair, an oxidized glutathione, and a heat shock protein (HSP) 90 inhibitor. SUMMARY OF PRESENTATIONS Science of Nuclear Excision Repair Dr.
Garon, Edward B., Dubinett, Steven M.
openaire +4 more sources
Journal of Medical Case Reports, 2021 Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer.
Rosa Montero-Macias +12 more
doaj +1 more source
Pyridazine Based Compounds with PARP-1 Inhibitory Activity
Archives of Pharmaceutical Sciences Ain Shams University, 2023 Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman +3 more
doaj +1 more source
Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date [PDF]
Seminars in Radiation Oncology, 2022 Radiation resistance remains a huge clinical problem for cancer patients and oncologists in the 21st century. In recent years, the mammalian DNA damage response (DDR) has been extensively characterized and shown to play a key role in determining cellular survival following ionizing radiation exposure.
Derby, Sarah J. +2 more
openaire +2 more sources
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Nowotwory, 2022 Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells ...
Katarzyna Zubik +3 more
doaj +1 more source
Journal of Infection in Developing Countries, 2022 Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Dimitra Ioanna Lampropoulou +6 more
doaj +1 more source
Adverse events of targeted therapies approved for women's cancers
International Journal of Women's Dermatology, 2021 Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle ...
Mathilde Saint-Ghislain, MD +2 more
doaj +1 more source
Novel poly(ADP-ribose) polymerase-1 inhibitors
Bioorganic & Medicinal Chemistry Letters, 2006 Synthesis and activity of a series of 3-aroyl-derived analogs of novel pyrrolocarbazole 1 as poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are disclosed.
Derek Dunn +3 more
openalex +4 more sources